XTL Biopharmaceuticals Ltd. (XTLB) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 975,912.64 |
| Enterprise Value | 1.17M |
| P/E Ratio | -0.6 |
| PEG Ratio | 0.01 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | -17.02 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -3.9 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | December 31, 2025 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -41.98 |
| Return On Equity | -2.69 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -752,000 |
| Net Income | -6.97M |
| Diluted EPS | -16 |
Balance Sheet
| Total Cash | 144,000 |
| Total Cash/Share | 0.02 |
| Total Debt | 269,000 |
| Total Debt/Equity | -1.06 |
| Current Ratio | 0.4 |
| Book Value Per Share | -0.03 |
Price History
| 52-Week Change | -64.11 |
| 52-Week High | 5.64 |
| 52-Week Low | 1.77 |
| Moving Average 50 Days | 2.37 |
| Moving Average 200 Days | 2.75 |
Statistics
| Average Volume | 7,754 |
| Shares Outstanding | 946,243 |
| % Held by Institutions | 1.8 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
| Last Split Date | March 25, 2026 |
AD
